International patterns and trends in ovarian cancer incidence, overall and by histologic subtype

International Journal of Cancer

Volumn 140, Issue 11, 2017, Pages 2451-2460

  Coburn, S B ^a   Bray, F ^b   Sherman, M E ^c   Trabert, B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c MAYO CLINIC   (United States)

Author keywords

histologic subtype; incidence trends; international; ovarian cancer

Indexed keywords

ARTICLE; ASIA; ASIAN; CANCER INCIDENCE; CAUCASIAN; CLEAR CELL CARCINOMA; DENMARK; EASTERN EUROPE; ENDOMETRIOID CARCINOMA; GEOGRAPHIC DISTRIBUTION; HEREDITY; HUMAN; JAPAN; NORTH AMERICA; OVARY CANCER; POLAND; SOUTHERN EUROPE; UNITED STATES; FACTUAL DATABASE; FEMALE; INCIDENCE; OVARIAN NEOPLASMS; PATHOLOGY; REGISTER;

DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; OVARIAN NEOPLASMS; REGISTRIES;

EID: 85016953626     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30676     Document Type: Article

References (47)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
2. Klint A, Tryggvadottir L, Bray F, et al. Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol 2010;49:632–43.
3. Sant M, Chirlaque Lopez MD, Agresti R, et al. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer 2015;51:2191–2205.
4. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3–10.
5. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013.
6. La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev 2016;26:55–62.
7. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 2009;40:1213–23.
8. Galic V, Coleman RL, Herzog TJ. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Curr Cancer Drug Targets 2013;13:698–707.
9. Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol 2016;34:2888–98.
10. Kaku T, Ogawa S, Kawano Y, Histological classification of ovarian cancer. Med Electron Microsc 2003;36:9–17.
11. Kurman RJ, Carcangiu M, Herrington CS, et al. WHO classification of tumours of female reproductive organs, World Health Organization, 4th edn., vol. 6, 2014.
12. Slayton RE. Management of germ cell and stromal tumors of the ovary. Semin Oncol 1984;11:299–313.
13. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer – shifting the paradigm. Hum Pathol 2011;42:918–31.
14. Zbuk K, Anand SS. Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 2011;66:1–7.
15. Gnagy S, Ming EE, Devesa SS, et al. Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. Epidemiology (Cambridge, MA) 2000;11:102–5.
16. Malvezzi M, Carioli G, Rodriguez T, et al. Global trends and predictions in ovarian cancer mortality. Ann Oncol 2016;27:2017–25.
17. Lowe KA, Chia VM, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 2013;130:107–14.
18. Sung PL, Chang YH, Chao KC, et al. Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecol Oncol 2014;133:147–54.
19. Ferlay J, Bray F, Steliarova-Foucher E, et al. Cancer incidence in five continents, CI5plus. IARC CancerBase No. 9. Lyon: International Agency for Research on Cancer, 2014.
20. Forman D, Bray F, Brewster DH, et al. eds. Cancer incidence in five continents, vol. X. Lyon: International Agency for Research on Cancer, 2014.
21. Segi M, Fujisaku S, Kurihara M. Geographical observation on cancer mortality by selected sites on the basis of standardised death rate. Gan 1957;48:219–25.
22. Doll R, Payne P, Waterhouse J. Cancer incidence in five continents: a technical report. Berlin: Springer-Verlag, 1966.
23. Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol 1995;141:300–4.
24. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet (London, England) 2008;371:303–14.
25. dos Santos Silva I, Swerdlow AJ. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br J Cancer 1995;72:485–92.
26. Braem MG, Onland-Moret NC, van den Brandt PA, et al. Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 2010;172:1181–9.
27. Voigt LF, Harlow BL, Weiss NS. The influence of age at first birth and parity on ovarian cancer risk. Am J Epidemiol 1986;124:490–1.
28. Cramer DW, Hutchison GB, Welch WR, et al. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711–6.
29. Yang HP, Anderson WF, Rosenberg PS, et al. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States. J Clin Oncol 2013;31:2146–51.
30. the ESHRE Capri Workshop Group, Europe the continent with the lowest fertility. Hum Reprod Update 2010;16:590–602.
31. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700–10.
32. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807–16.
33. Zlotogora J. Genetics and genomic medicine in Israel. Mol Genet Genomic Med 2014;2:85–94.
34. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198–200.
35. Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188–90.
36. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235–40.
37. Liede A, Narod SA. Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 2002;20:413–24.
38. Shanmughapriya S, Nachiappan V, Natarajaseenivasan K. BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: special reference to Asia. Oncology 2013;84:226–32.
39. Arumugam K, Templeton AA. Endometriosis and race. Aust N Z J Obstet Gynaecol 1992;32:164–5.
40. Cramer DW, Missmer SA. The epidemiology of endometriosis. Ann N Y Acad Sci 2002;955:11–22; discussion 34–6, 396–406.
41. Yan Y, Wu R, Li S, et al. Meta-analysis of association between the TP53 Arg72Pro polymorphism and risk of endometriosis based on case-control studies. Eur J Obstet Gynecol Reprod Biol 2015;189:1–7.
42. Li J, Chen Y, Mo Z, et al. TP53 Arg72Pro polymorphism (rs1042522) and risk of endometriosis among Asian and Caucasian populations. Eur J Obstet Gynecol Reprod Biol 2015;189:73–8.
43. Sangi-Haghpeykar H, Poindexter AN. III. Epidemiology of endometriosis among parous women. Obstet Gynecol 1995;85:983–92.
44. Missmer SA, Hankinson SE, Spiegelman D, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 2004;160:784–96.
45. Worley MJ, Welch WR, Berkowitz RS, et al. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci 2013;14:5367–79.
46. Hammer A, Rositch AF, Kahlert J, et al. Global epidemiology of hysterectomy: possible impact on gynecological cancer rates. Am J Obstet Gynecol 2015;213:23–9.
47. Merrill RM. Impact of hysterectomy and bilateral oophorectomy on race-specific rates of corpus, cervical, and ovarian cancers in the United States. Ann Epidemiol 2006;16:880–7.